Unusual expression of red fluorescence at M phase induced by anti-microtubule agents in HeLa cells expressing the fluorescent ubiquitination-based cell cycle indicator (Fucci)

Biochemical and Biophysical Research Communications

Volumn 428, Issue 2, 2012, Pages 224-229

  Honda Uezono, Asumi ^a   Kaida, Atsushi ^a   Michi, Yasuyuki ^a   Harada, Kiyoshi ^a   Hayashi, Yoshiki ^b   Hayashi, Yoshio ^b   Miura, Masahiko ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Anti microtubule agents; Fluorescent ubiquitination based cell cycle indicator (Fucci); Mitosis; Mitotic catastrophe; Ubiquitination

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; FLUORESCENT UBIQUITINATION BASED CELL CYCLE INDICATOR; INDICATOR; KPU 133; NOCODAZOLE; PLINABULIN; RED FLUORESCENT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE M PHASE; CONTROLLED STUDY; G2 PHASE CELL CYCLE CHECKPOINT; HELA CELL; METAPHASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UBIQUITINATION;

CELL DIVISION; DIKETOPIPERAZINES; FLUORESCENCE; HELA CELLS; HUMANS; LUMINESCENT PROTEINS; MICROTUBULES; MITOSIS; NOCODAZOLE; TUBULIN MODULATORS; UBIQUITIN-PROTEIN LIGASES;

EID: 84869206886     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.10.014     Document Type: Article

References (17)

1. Nogales E. Structural insights into microtubule function. Annu. Rev. Biochem. 2000, 69:277-302.
2. Zhou J., Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr. Med. Chem. Anti-Cancer Agents 2005, 5:65-71.
3. Dumontet C., Jordan M.A. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 2010, 9:790-803.
4. Yamazaki Y., Sumikura M., Masuda Y., Hayashi Y., Yasui H., Kiso Y., Chinen T., Usui T., Yakushiji F., Potts B., Neuteboom S., Palladino M., Lloyd G.K., Hayashi Y. Synthesis and structure-activity relationships of benzophenone-bearing diketopiperazine-type anti-microtubule agents. Bioorg. Med. Chem. 2012, 20:4279-4289.
5. Lin C.M., Ho H.H., Pettit G.R., Hamel E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 1989, 28:6984-6991.
6. Daenen L.G., Roodhart J.M., Shaked Y., Voest E.E. Vascular disrupting agents (VDAs) in anticamcer therapy. Curr. Clin. Pharmacol. 2010, 5:178-185.
7. Nicholson B., Lloyd G.K., Miller B.R., Palladino M.A., Kiso Y., Hayashi Y., Neulteboom S.T.C. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anti-Cancer Drugs 2006, 17:25-31.
8. Yamazaki Y., Tanaka K., Nicholson B., Deyanat-Yazdi G., Potts B., Yoshida T., Oda A., Kitagawa T., Orikasa S., Kiso Y., Yasui H., Akamatsu M., Chinen T., Usui T., Shinozaki Y., Yakushiji F., Miller B.R., Neuteboom S., Palladino M., Kanoh K., Lloyd G.K., Hayashi Y. Synthesis and structure-activity relationship study of antimicrotubule agents phenylahistin derivatives with a didehydropiperazine-2,5-dione structure. J. Med. Chem. 2012, 55:1056-1071.
9. Mita M.M., Spear M.A., Yee L.K., Mita A.C., Heath E.I., Papadopoulos K.P., Federico K.C., Reich S.D., Romero O., Malburg L., Pilat M., Lloyd G.K., Neuteboom S.T., Cropp G., Ashton E., LoRusso P.M. Phase 1 first-in-human trial of the vascular disrupting agent plinabulin (NPI-2358) in patients with solid tumors or lymphomas. Clin. Cancer Res. 2010, 16:5892-5899.
10. Singh A.V., Bandi M., Raje N., Richardson P., Palladino M.A., Chauhan D., Anderson K.C. A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells. Blood 2011, 117:5692-5700.
11. Sakaue-Sawano A., Kurokawa H., Morimura T., Hanyu A., Hama H., Osawa H., Kashiwagi S., Fukami K., Miyata T., Miyoshi H., Imamura T., Ogawa M., Masai H., Miyawaki A. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell 2008, 132:487-498.
12. Nitta M., Kobayashi O., Honda S., Hirota T., Kuninaka S., Marumoto T., Ushio Y., Saya H. Spindle checkpoint function is required for mitotic catastrophe induced by DNA-damaging agents. Oncogene 2004, 23:6548-6558.
13. Blajeski A.L., Phan V.A., Kottke T.J., Kaufmann S.H. G1 and G2 cell-cycle arrest following microtubule depolymerization in human breast cancer cells. J. Clin. Invest. 2002, 110:91-99.
14. Kaida A., Miura M. Visualizing the effect of hypoxia on fluorescence kinetics in living HeLa cells using the fluorescent ubiquitination-based cell cycle indicator (Fucci). Exp. Cell Res. 2012, 318:288-297.
15. Kaida A., Sawai N., Sakaguchi K., Miura M. Fluorescence kinetics in HeLa cells after treatment with cell cycle arrest inducers visualized with Fucci (fluoresent ubiquitination-based cell cycle indicator). Cell Biol. Int. 2011, 35:359-363.
16. Nishitani H., Lygerou Z., Nishimoto T. Proteolysis of DNA replication licensing factor Cdt1 in S-phase is performed independently of geminin through its N-terminal region. J. Biol. Chem. 2004, 279:30807-30816.
17. Hashimoto T., Kikkawa U., Kamada S. Contribution of caspase(s) to the cell cycle regulation at mitotic phase. Plos ONE 2011, 6:e18449.